Armatus Bio Completes Pivotal Animal Study Demonstrating Delivery, Safety, and Activity of Their CMT1A Gene Therapy and is Now Preparing to Advance Project to Clinical Trials

Armatus Bio Completes Pivotal Animal Study Demonstrating Delivery, Safety, and Activity of Their CMT1A Gene Therapy and is Now Preparing to Advance Project to Clinical Trials

Armatus Bio acquired the CMT1A gene therapy that was developed by Dr. Kleopas Kleopa and Dr. Scott Harper in a previous CMTRF-funded project to advance it further as a therapeutic. To demonstrate this therapy could be a safe and effective treatment for CMT1A, Armatus...
Inaugural Zero-K Run Raises Awareness for CMT and CMTRF

Inaugural Zero-K Run Raises Awareness for CMT and CMTRF

When many people think of the word “race” they imagine a 5k, 10k and even a half-marathon. But, what about a new type of run that directly benefits patients with Charcot-Marie-Tooth disease and covers no distance at all—A Zero-K Run. A Zero-K Run is exactly what it...